Key Takeaways:
- 21Shares launched an Injective (INJ) exchange-traded product (ETP) with staking on Euronext Paris and Amsterdam.
- The Injective Staking ETP (AINJ) tracks INJ performance, reinvests staking yields, and is supported by 25 financial institutions.
- AINJ manages $128.6 million in assets, charges a 2.5% fee, and offers staking rewards estimated at 19.38%.
21Shares has launched an Injective (INJ) exchange-traded product (ETP) with staking on the Euronext exchanges, adding INJ to the list of cryptocurrencies available through traditional financial products.
The Injective Staking Exchange Traded Product (AINJ) tracks INJ’s performance and reinvests staking yields.
Introducing AINJ, the Injective Staking Exchange Traded Product (ETP), launched by 21Shares.
— Injective 🥷 (@injective) July 18, 2024
This innovative product offers exposure to $INJ via major traditional finance exchange venues and brokerages while also capturing staking rewards.
1/9🧵 pic.twitter.com/tL3eX4D5We
This ETP, physically backed by INJ stored in cold storage, trades on Euronext Paris and Amsterdam, supported by 25 financial institutions.
AINJ manages $128.6 million in assets with a 2.5% fee.
Given Injective’s proof-of-stake mechanism, AINJ can stake INJ to earn rewards, currently estimated at 19.38%.
Injective launched in 2021, integrated with Ethereum and Solana, and is supported by Binance and Mark Cuban.
Despite a total value locked (TVL) of $105 million and only 60 validators, Injective aims to increase its user base and liquidity.
Its competitive advantages include an open liquidity pool and a real-world asset module.
About The Author
Victor Fawole, a seasoned Web3 content creator and social media influencer, excels in bringing the pulse of the crypto world to our readers.
With a keen eye for emerging trends and a talent for engaging storytelling, Victor’s articles offer a fresh perspective on the ever-evolving digital currency landscape.
Check Victor out on:
